Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view

Table 1 Clinical trials (centered on phase 2 or phase 3) that target the gut microbiota involved in non-alcoholic fatty liver disease

NCT number	Condition(s)	Intervention	Phase	Status	Country
NCT01355575	NAFLD	Antibiotics	Phase 4	Terminated	United Kingdom
NCT02329405	NAFLD	Antibiotics	Phase 4	Completed	Finland
NCT01759628	NAFLD	Antibiotics	Phase 2	Completed	Iran
NCT01712711	NAFLD	Antibiotics	Phase 2	Completed	Iran
NCT01654549	NAFLD	Antibiotics	Phase 2	Completed	Iran
NCT01876108	Fatty liver	Antibiotics	Phase 2	Completed	Iran
NCT02510599	NASH	Antibiotics	Phase 2	Completed	United States
NCT00068094	Fatty liver	Probiotics	Phase 1/Phase 2	Terminated	United States
NCT02972567	Metabolic syndrome/NAFLD	Probiotics	Phase 2	Unknown status1	Spain
NCT03511365	NAFLD	Probiotics	Phase 1/Phase 2	Terminated	United States
NCT03585413	Obesity/NAFLD	Probiotics	Phase 3	Recruiting	Germany
NCT04175392	Fatty liver disease	Probiotics	Phase 1/Phase 2	Not yet recruiting	United States
NCT02530138	NASH	Synbiotics	Phase 2/Phase 3	Unknown status1	Iran
NCT01791959	NASH	Synbiotics	Phase 2/Phase 3	Completed	Iran
NCT02496390	Diabetes mellitus/NAFLD	FMT	Phase 1/Phase 2	Completed	Canada
NCT02530385	Obesity/NAFLD	FMT	Phase 1/Phase 2	Completed	United States
NCT02741518	Obesity/NAFLD	FMT	Phase 1/Phase 2	Active, not recruiting	United States
NCT02970877	Obesity/NAFLD	FMT	Phase 2	Recruiting	Canada
NCT02050607	Metabolic syndrome/NAFLD	FMT	Phase 3	Unknown status1	Italy
NCT02862249	Cirrhosis	FMT	Phase 3	Recruiting	United Kingdom
NCT03014505	Cirrhosis	FMT	Phase 1/Phase 2	Unknown status1	China

¹Study has passed its completion date and status has not been verified in more than two years. Data from https://clinicaltrials.gov/. FMT: Fecal microbiota transplantation; NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis.